DDNews

1 week ago | drugdiscoverynews.com | Bree Coven Foster

Synthetic DNA is increasingly used for gene therapies due to its fast production and improved scalability compared to traditional plasmid-based methods. Credit: iStock.com/ktsimageSynthetic DNA is increasingly used for gene therapies due to its fast production and improved scalability compared to traditional plasmid-based methods.

1 week ago | drugdiscoverynews.com | Allison Whitten

After two decades working in leadership positions at big pharmaceutical companies like AstraZeneca and Novartis, immunologist and emergency physician Volkan Manga wanted to go in a new direction. He realized that as he watched some drugs pass through clinical trials and reach real patients, many more drugs with great potential sat by the wayside.

1 week ago | drugdiscoverynews.com | Bree Coven Foster

In the world of drug development, securing timely access to fill/finish services can often pose a critical bottleneck, especially for clinical trials requiring small-volume production. Fill/finish refers to the final steps in the production of injectable pharmaceutical drug substances, including the process of filling vials with a drug substance, sealing them, and ensuring they are sterile and ready for use in clinical settings.

2 weeks ago | drugdiscoverynews.com | Bree Coven Foster

Duchenne muscular dystrophy (DMD) has long been understood as a disease driven by the absence of dystrophin, a protein essential for maintaining muscle integrity. Most therapeutic efforts have focused on restoring dystrophin through gene therapy, exon-skipping, or other genetic approaches. However, emerging research suggests that dystrophin’s role extends beyond structural support — it also plays a critical part in regulating muscle regeneration.

2 weeks ago | drugdiscoverynews.com | Bree Coven Foster

From understanding immune responses to screening new drug candidates, flow cytometry plays a critical role in modern biomedical research. By rapidly analyzing thousands of cells per second, researchers can gather precise, multiparametric data at the single-cell level. Recent innovations in automation and high-throughput screening have further expanded the technology’s potential, making it a powerful tool for drug discovery.